U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H24O6
Molecular Weight 372.4117
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of DIHYDROXYBERGAMOTTIN

SMILES

C\C(CC[C@@H](O)C(C)(C)O)=C/COC1=C2C=CC(=O)OC2=CC3=C1C=CO3

InChI

InChIKey=IXZUPBUEKFXTSD-INMULRNOSA-N
InChI=1S/C21H24O6/c1-13(4-6-18(22)21(2,3)24)8-10-26-20-14-5-7-19(23)27-17(14)12-16-15(20)9-11-25-16/h5,7-9,11-12,18,22,24H,4,6,10H2,1-3H3/b13-8+/t18-/m1/s1

HIDE SMILES / InChI

Molecular Formula C21H24O6
Molecular Weight 372.4117
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 1
Optical Activity UNSPECIFIED

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9757148 | https://www.ncbi.nlm.nih.gov/pubmed/25253884 | https://www.ncbi.nlm.nih.gov/pubmed/9351897 | https://www.ncbi.nlm.nih.gov/pubmed/23146034

6',7'-Dihydroxybergamottin is a natural furanocoumarin found principally in grapefruit juice. Along with the chemically related compound bergamottin, it is believed to be responsible for a number of grapefruit–drug interactions, in which the consumption of the juice affects the metabolism of a variety of pharmaceutical drugs.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
59.0 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
2005 Oct
Patents

Patents

Sample Use Guides

0.60 or 1.85 mg Dihydroxybergamottin once weekly
Route of Administration: Oral
HepG2-GS-3A4 cells, transduced with both hamster glutamine synthetase (GS) gene and human CYP3A4 gene were used for activity evaluation. One-hundred-thousand cells were seeded onto 24-well culture plates and grown to confluence. When cells were nearly confluent, the medium was replaced by 0.3 ml of phosphate-buffered saline (PBS) containing nifedipine (at a concentration of 28.9 mm) as a substrate of CYP3A4 and bergamottin (at a concentration of 0–3.0 mkm) or DHB (at a concentration of 0–5.9 mkm) as an inhibitor of CYP3A4. Samples of 0.1 ml were collected from the solution sequentially at 1 h after incubation at 37°C with 5%CO2. The concentration of oxidised nifedipine in these solutions was measured by high-performance liquid chromatography (HPLC).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:20:53 GMT 2023
Edited
by admin
on Fri Dec 15 16:20:53 GMT 2023
Record UNII
S2O194AWTV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIHYDROXYBERGAMOTTIN
MI  
Common Name English
DIHYDROXYBERGAMOTTIN, (+)-
Common Name English
(R)-6',7'-DIHYDROXYBERGAMOTTIN
Common Name English
(R)-17,18-DIHYDROXYBERGAMOTTIN
Common Name English
6',7'-DIHYDROXYBERGAMOTTIN
Common Name English
7H-FURO(3,2-G)(1)BENZOPYRAN-7-ONE, 4-(((2E,6R)-6,7-DIHYDROXY-3,7-DIMETHYL-2-OCTEN-1-YL)OXY)-
Systematic Name English
BERGAMOTTIN DIHYDROXYBERGAMOTTIN [MI]
Common Name English
Code System Code Type Description
WIKIPEDIA
Dihydroxybergamottin
Created by admin on Fri Dec 15 16:20:53 GMT 2023 , Edited by admin on Fri Dec 15 16:20:53 GMT 2023
PRIMARY
CAS
145414-76-2
Created by admin on Fri Dec 15 16:20:53 GMT 2023 , Edited by admin on Fri Dec 15 16:20:53 GMT 2023
NON-SPECIFIC STEREOCHEMISTRY
MERCK INDEX
m2429
Created by admin on Fri Dec 15 16:20:53 GMT 2023 , Edited by admin on Fri Dec 15 16:20:53 GMT 2023
PRIMARY
CAS
264234-05-1
Created by admin on Fri Dec 15 16:20:53 GMT 2023 , Edited by admin on Fri Dec 15 16:20:53 GMT 2023
PRIMARY
PUBCHEM
12082365
Created by admin on Fri Dec 15 16:20:53 GMT 2023 , Edited by admin on Fri Dec 15 16:20:53 GMT 2023
PRIMARY
FDA UNII
S2O194AWTV
Created by admin on Fri Dec 15 16:20:53 GMT 2023 , Edited by admin on Fri Dec 15 16:20:53 GMT 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
IRREVERSIBLE INHIBITOR